News & Updates
Filter by Specialty:

Novel tool spots potentially inappropriate prescribing in T2D
A new tool for identifying potentially inappropriate prescribing (PIP) in people with type 2 diabetes (T2D) has been validated in the outpatient setting, according to an Ethiopian study.
Novel tool spots potentially inappropriate prescribing in T2D
18 Jul 2024
Wearables on par with conventional tools for cardiac monitoring
Electrocardiogram (ECG)- and photoplethysmography (PPG)-based wearable devices demonstrate effectiveness for paroxysmal atrial fibrillation (AF) detection following cryptogenic stroke or embolic stroke of undetermined source (ESUS) similar to that of conventional management, results of a Singapore study have shown.
Wearables on par with conventional tools for cardiac monitoring
18 Jul 2024
Nirmatrelvir-ritonavir bests molnupiravir in COVID-19 patients with advanced kidney disease
In a retrospective observational study, nirmatrelvir-ritonavir trumps molnupiravir in reducing the risk of all-cause mortality at 90 days and hospitalization in COVID-19 patients with advanced kidney disease (chronic kidney disease [CKD] stage 4, ie, eGFR <30 mL/min/1.73 m2).
Nirmatrelvir-ritonavir bests molnupiravir in COVID-19 patients with advanced kidney disease
18 Jul 2024
Smoking, occupational dust exposure a risk factor for idiopathic pulmonary fibrosis
Smoking and occupational dust exposure appear to contribute to an increased risk of idiopathic pulmonary fibrosis (IPF), according to a study.
Smoking, occupational dust exposure a risk factor for idiopathic pulmonary fibrosis
18 Jul 2024
Novel IL-17A inhibitor helps dial down psoriatic arthritis disease activity
Potent and selective inhibition of IL-17A by izokibep produced a rapid improvement in disease activity across multiple psoriatic arthritis (PsA) domains, according to preliminary data from a phase IIb/III trial.
Novel IL-17A inhibitor helps dial down psoriatic arthritis disease activity
17 Jul 2024
Upadacitinib proves long-term efficacy in RA
Upadacitinib remains effective through 5 years in patients with rheumatoid arthritis (RA) who have inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), with no new safety signals, as shown by the results of the phase III long-term extension (LTE) of SELECT-NEXT.
Upadacitinib proves long-term efficacy in RA
17 Jul 2024
Reduced kidney function after stroke ups risk of recurrence, dementia
Patients with declining kidney function following a cerebrovascular event are at increased risk of major adverse cardiovascular events (MACE), dementia, and mortality at 2 years, according to a study. However, a higher risk of death is also noted for those with a large increase in kidney function.